RARE - Ultragenyx Pharmaceutical Inc.

RARE

$14.90 +0.00 (+0.00%)

Pre-Market: $14.90 +0.00 (+0.00%)

Last updated: Oct 15, 2026 09:24

52-Week Range

$14.90

$12.73 $14.90 $39.89

Fundamentals Overview

Ultragenyx Pharmaceutical Inc. is near the low of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/B 316.5 P/S 2.05

Risk (Beta)

0.35 — lower vol

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell

Buy

Hold — 37% confidence Risk: Lower Volatility — Beta 0.35. Diversify and only invest what you can afford to lose.

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap

$1.47B

P/E (TTM)

N/A

EPS (TTM)

N/A

Dividend Yield

N/A

52-Week Range

$12.73 - $39.89

Volume vs Avg

N/A

Beta

0.35

About

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adu...

Sector: Healthcare

Headquarters: US

Website: www.ultragenyx.com

Beta: 0.35 (Less volatile than market)

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

Metric	Value
Valuation
P/E (TTM)	N/A
PEG (TTM)	N/A
P/B (TTM)	316.5
P/S (TTM)	2.05
Profitability
ROE (TTM)	N/A
ROA (TTM)	-44.37%
Revenue growth (YoY)	N/A
Net margin (TTM)	-81.73%
Gross margin (TTM)	83.11%
Operating margin (TTM)	-73.67%
Debt to equity (TTM)	90.54

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for RARE.

Loading analyst coverage...

Price target data is not available for this symbol from the current data source.

Stock Grades (Institutions)

No stock grades available for this symbol.

No price targets, ratings snapshot, or grades available for this symbol.